Peak region ^a	Peak region ^a	Freq. ^b	Max./min. gene dosage ^c	Correlating genes ^d
(Cytoband)	(MB)	(%)	(copy no.)	
Recurrent high level amplification				
3q26.1-qter	166.2-199.5	8	4.5 (9)	 PDCD10, PHC3, ZNF639, FXR1, PARL, DVL3, ABCF3, ALG3, EIF4G1, SFRS10, DGKG, EIF4A2, RFC4, CCDC50, PPP1R2, PAK2, NCBP2, DLG1, BDH1, FLYTTD1
5p15.2-pter	1.0-12.1	8	4 (15)	CLPTM1L , MED10, FASTKD3, CCT5, DAP
9p24.1-2	2.7-6.0	4	13.5 (27)	KIAA0020, RCL1
11q13.2-3	68.6-70.6	4	10 (20)	FADD
11q22.1-2	100.2-102.0	5	36 (72)	YAP1, BIRC3, BIRC2
20q11.21-22	30.0-33.0	5	3.4 (9)	POFUT1, KIF3B, MAPRE1, SNTA1, EIF2S2, AHCY
21q22.11-2	32.9-39.6	4	7.5 (15)	TTC3, BRWD1
Homozygous deletion ^e				
5q13.2	67.4-71.7	1	0 (0)	SMN2
6p21.1-p12.1	44.1-54.1	1	0 (0)	-
8q24.23	136.6-139.3	1	0 (0)	-
9p21.1-3	22.6-29.6	1	0 (0)	MOBKL2B
10q23.31	88.2-92.1	3	0 (0)	-
13q34	111.7-114.1	1	0 (0)	-

Table S1. Recurrent high level amplifications and homozygous deletions in locally advanced cervical cancer.

^aPeak region of high level amplifications is the region with more than 25% higher amplitude than surrounding region. Peak region of homozygote deletions is the region with a gene dosage of zero.

^bFrequency is the median percentage of tumors with the alteration. ^cGene dosage is absolute DNA copy number divided by ploidy. Maximum (gain) or minimum (loss) gene dosage and the ^dGenes within the peak region showing a correlation between gene dosage and expression are ordered by DNA location.

^eHomozygote deletions were seen in only few tumors and were not detected as recurrent in statistical analysis.